Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global diabetic retinopathy market size was valued at USD 6.6 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2022 to 2030. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are among the major factors anticipated to boost market growth over the forecast period. The market is further propelled by the increasing awareness about diabetes management and care and new product launches. Diabetes is a serious and growing problem globally, where the inefficiency of the pancreas to produce insulin results in an increase in blood glucose levels. Diabetic retinopathy is caused by damage to the blood vessels in the retina. This leads to blurred vision and vision loss in most cases.

Risk factors such as high blood sugar levels and poor monitoring of the constant fluctuating BG levels are said to fuel the cause of diabetic retinopathy. Early detection of diabetes in patients, treatment correction, constant self-monitoring by the patients using advanced tools, and adoption of a healthier lifestyle may reduce the damage to the retinal blood vessels, decreasing the prevalence of diabetic retinopathy among patients. Despite all the necessary measures adopted by the diabetic population, diabetic retinopathy can lead to permanent blindness, based on the disease stage and severity of the condition. According to the Department of Assistive and Rehabilitative Services (DARS), Texas, around 78.0% of cases of diabetic retinopathy were reported in 2013 which may eventually lead to loss of vision.

In addition, as per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was among the leading causes of blindness in the U.K. in 2018. Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Additionally, the WHO claims that the world’s aging population will more than double by 2050, as compared to that in 2020. Hence, it is important to maintain a healthy lifestyle, control obesity, and continuously monitor BG levels in the vulnerable population.

The COVID-19 pandemic impacted the market negatively. Closure of manufacturing units, dramatic economic decline, national lockdowns, shutting of logistic services, and reduced diagnostic activities due to the fear of virus spread were few among the many reasons for the dip in the market. Postponement of sales activities, reduction in R&D activities undertaken by leaders to launch advanced products, and most importantly, economic setbacks experienced by patients led to the dramatic decline in 2020. However, the market is said to bounce back by mid-2022.

Management Insights

The anti-VEGF drugs accounted for the largest revenue share of 92.5% in 2021 owing to their efficiency and efficacy in the treatment of diabetic retinopathy. The anti-VEGF drugs are popularly used for the treatment of Proliferative Diabetic Retinopathy (PDR). Anti-VEGF agents were found to be more beneficial in PDR, especially in cases with vitreous hemorrhage, neovascular glaucoma, and prior to the vitrectomy procedure. On the other hand, Intraocular steroidal injection is a relatively new treatment for diabetic retinopathy and Diabetic Macular Edema (DME) compared with anti-VEGF agents and is slowly gaining momentum. The injections contain corticosteroid-based drugs that control cellular proliferation. Among all corticosteroids being examined, Triamcinolone (Durezol) has shown the best therapeutic performance and has a strong market presence. Other segments include laser surgery and vitrectomy as retinopathy management tools.

Type Insights

The non-proliferative diabetic retinopathy segment dominated the diabetic retinopathy market and accounted for the largest revenue share of 71.5% in 2021. The growing geriatric population and rising incidences of blindness caused due to diabetes are the key factors accounting for its large share. Furthermore, increasing demand for regular retinal screening for long-time diabetic patients is also expected to boost segment growth. On the other hand, the proliferative diabetic retinopathy segment is expected to witness a lucrative CAGR of 6.9% from 2022 to 2030.

The Proliferative Diabetic Retinopathy (PDR) segment is expected to witness a higher CAGR of 5.6% during the forecast period. It is considered to be an advanced stage of retinopathy. In this case, the fragile blood vessels grow within the retina and the vitreous humor, resulting in blurred vision and blindness. It may lead to macular edema, showing no symptoms in the early stages. It is diagnosed through comprehensive eye exams, such as tonometry, visual acuity tests, and many others. It is treated with laser surgery that allows shrinkage of the blood vessels.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 37.9% in 2021. The presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to drug development, and the presence of high patient and practitioner awareness levels are some of the drivers of this market. In Asia Pacific, the market is expected to witness a lucrative CAGR of 7.1% from 2022 to 2030 due to the presence of high unmet medical needs, coupled with rapidly rising patient awareness regarding effective diagnostic procedures for diabetes and rising healthcare expenditures in the emerging economies of India and China. Latin America and Middle East regions are also anticipated to witness lucrative growth over the forecast period.

Key Companies & Market Share Insights

Major players are focusing on collaborations, partnerships, mergers, and other strategic activities to improve their market position. Market leaders face increased competition from new drug launches and new management treatment approval from regulatory bodies, making it difficult for them to sustain themselves in the ever-changing market. However, heavy investments in R&D conducted by market leaders are said to boost the market growth. Some of the prominent players in the diabetic retinopathy market include:

• Bayer AG

• Allergan plc

• Novartis AG

• Oxurion NV

• Sirnaomics Inc.

• Genentech

• Alimera Sciences

• Ampio Pharmaceuticals

• BCN Peptides

• Kowa Company, Ltd.

Diabetic Retinopathy Market Report Scope

Segments Covered in the Report 

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global diabetic retinopathy market report on the basis of type, management, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Proliferative Diabetic Retinopathy

  • Non-proliferative diabetic retinopathy

• Management Outlook (Revenue, USD Million, 2018 - 2030)

  • Anti-VEGF

  • Intraocular Steroid Injection

  • Laser Surgery

  • Vitrectomy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE